Effects of zymosan-activated plasma and phorbol myristate acetate on isolated, perfused rabbit lungs.
The effects of complement activation on pulmonary vascular permeability are disputed. In rabbit lungs perfused with autologous blood, zymosan activated plasma (ZAP) induced a moderate increase in pulmonary vascular resistance (PVR), but did not detectably change the vascular permeability within 2 h. The stronger neutrophil granulocyte (PMN) activator, phorbol myristate acetate (PMA), usually gave larger PVR increases and also increased pulmonary vascular permeability. Lungs from neutropenic animals, similarly perfused and given PMA, showed unchanged PVR reactions but had no apparent increase in vascular permeability. Lungs perfused with cell-free medium and given PMA displayed modest PVR increases, and no measurable permeability change. The lung preparatory procedure itself markedly influenced leukocyte circulation. Exsanguination of lung donors decreased the concentration of circulating PMN significantly, and they virtually disappeared from the perfusate within minutes after start of lung perfusion. PMN-mediated effects must therefore have been caused by cells already sequestered in the lungs. We conclude that ZAP does not induce an increased pulmonary vascular permeability in isolated, perfused rabbit lungs, in contrast to PMA. The permeability effects of PMA appear to be PMN dependent.
D000818:Animals; D001772:Blood Cell Count; D002199:Capillary Permeability / Q000187:drug effects; D005260:Female; D066298:In Vitro Techniques; D008168:Lung / Q000187:drug effects*; D008297:Male; D010477:Perfusion; D010949:Plasma / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects; D011817:Rabbits; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D015054:Zymosan / Q000494:pharmacology*
D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate